BMS-754807

For research use only. Not for use in humans.

目录号:S1124

BMS-754807 Chemical Structure

CAS No. 1001350-96-4

BMS-754807是一种有效的IGF-1R/InsR可逆性抑制剂,在无细胞试验中IC50为1.8 nM/1.7 nM,对Met,Aurora A/B,TrkA/B和Ron作用稍弱,对Flt3, Lck,MK2,PKA,PKC等几乎没有抑制活性。Phase 2。

规格 价格 库存 购买数量  
RMB 1480.09 现货
RMB 2214.12 现货
RMB 6299.66 现货
RMB 16953.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的BMS-754807发表文献29篇:

产品安全说明书

IGF-1R抑制剂选择性比较

生物活性

产品描述 BMS-754807是一种有效的IGF-1R/InsR可逆性抑制剂,在无细胞试验中IC50为1.8 nM/1.7 nM,对Met,Aurora A/B,TrkA/B和Ron作用稍弱,对Flt3, Lck,MK2,PKA,PKC等几乎没有抑制活性。Phase 2。
特性 胰岛素样生长因子-1R/IR家族激酶的多重抑制剂
靶点
Insulin Receptor [1]
(Cell-free assay)
IGF-1R [1]
(Cell-free assay)
TrkB [1]
(Cell-free assay)
Met [1]
(Cell-free assay)
TrkA [1]
(Cell-free assay)
1.7 nM 1.8 nM 4.1 nM 5.6 nM 7.4 nM
体外研究

BMS-754807 有效抑制人类多种不同组织来源的肿瘤细胞系的生长,包括间充质(尤文氏肉瘤,横纹肌肉瘤,神经母细胞瘤,和脂肪肉瘤),上皮(乳腺,肺,胰腺,结肠,和胃),和造血(多发性骨髓瘤和白血病)组织,IC50值从5 nM 到 365 nM。BMS-754807 抑制 IGF-1R-Sal 细胞和 RH41细胞增殖,IC50分别为7 nM 和5 nM。BMS-754807作用于IGF-1R-Sal, Rh41 和 Geo细胞,抑制IGF-1R磷酸化,IC50分别为13 nM, 6 nM 和 21 nM。BMS-754807作用于 IGF-1R-Sal, Rh41 和Geo细胞,抑制Akt磷酸化,IC50 分别为22 nM, 13 nM 和 16 nM。BMS-754807诱导Rh41细胞凋亡。[1] BMS-754807作用于IGF-Sal 细胞系,抑制IGF-1R (IC50 = 13nM) 和下游靶点Akt (IC50 = 22nM) 和MAPK(IC50 = 13nM) 的磷酸化。[2] 在儿科临床前期试验计划(PPTP)中,BMS-754807作用于23种细胞系,平均EC50值为0.62 µM。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
IGF-Sal M2flSGtqdmG|ZTDhd5NigQ>? MWrpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEmJRj2xVkApUUN3MDC9JFE{dk1rIHHu[EB1cGViZH;3cpN1emWjbTD0ZZJo\XS|IFHreEApUUN3MDC9JFIzdk1rIHHu[EBOSVCNIDjJR|UxKD1iMUPuUUk> MnzuNVk4PzhyMkS=
IGF-Sal MnTnS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M4LhVGlEPTB;NzDuUS=> M{jsR|E6Pzd6MEK0
CCRF-CEM (ALL) NYm1cFV4T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4roZ542KM7:TR?= NH\xUI1FVVOR NFLyR2xKSzVyPUGuNlM6KM7:TR?= M4jKUlE6QTl4Mkey
PC3 NEniNotIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2nlUJ42KM7:TR?= NULaTWFHTE2VTx?= MoDTTWM2OD1yLkm2OUDPxE1? NIG2OnUyQTl7NkK3Ni=>
JD MXPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NGXsSXl,PSEQvF2= NFjMRZNFVVOR M3PYc2lEPTB;MD6zPVEh|ryP NHS3Z4wyQTl7NkK3Ni=>
DU145 NILuV3VIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NUe1Onp[hjVizszN NXz1UVVZTE2VTx?= MVnJR|UxRTFwNE[1JO69VQ>? NWTleFdIOTl7OU[yO|I>
KAG NWTz[YdDT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NEm4XoR,PSEQvF2= MkO3SG1UVw>? MlP0TWM2OD1zLk[2OUDPxE1? M{i1[VE6QTl4Mkey
K-562 (CML) MmTuS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFK0NnV,PSEQvF2= NWLwT5ltTE2VTx?= NGLUfIZKSzVyPUKuN|AzKM7:TR?= NYLRdpZ7OTl7OU[yO|I>
B6-P210 (Murine ALL) MmPLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Ml3BglUh|ryP NH3hcGFFVVOR MX\JR|UxRTFwMkmzJO69VQ>? NHLT[2MyQTl7NkK3Ni=>
LN CAP-FGC MX\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M1joRZ42KM7:TR?= M4LXN2ROW09? M2TLTmlEPTB;MT60N|Qh|ryP MkDNNVk6QTZ{N{K=
VW MmT2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NWHFbpIxhjVizszN M1\ENmROW09? MlvITWM2OD1yLkCxPUDPxE1? NXfjdoxkOTl7OU[yO|I>
MV411 (B Myelomonocytic) MoDhS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M3TWbJ42KM7:TR?= M37Qc2ROW09? MnPVTWM2OD1yLkOzJO69VQ>? M3rTWVE6QTl4Mkey
MDA-PCa-2b NVviO|VwT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NXjOdXo{hjVizszN NVrZ[md1TE2VTx?= MmPITWM2OD1yLkC5PEDPxE1? MWqxPVk6PjJ5Mh?=
LG NWO0OXppT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= Moq2glUh|ryP MUXEUXNQ NVHsPZBuUUN3ME2wMlA{QCEQvF2= M4frblE6QTl4Mkey
RS411 (B cell precursor-ALL) MlLKS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXP2UWlkhjVizszN NV3lUnVvTE2VTx?= MY\JR|UxRTBwMUCyJO69VQ>? NF\Ub5EyQTl7NkK3Ni=>
22-r-1 MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mk\3glUh|ryP Mo\vSG1UVw>? NVPEepo2UUN3ME2wMlE4PSEQvF2= NYS5NnJvOTl7OU[yO|I>
5838 MYfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NVLSW2RDhjVizszN NEDROFVFVVOR MUTJR|UxRTBwMEO0JO69VQ>? M1exSVE6QTl4Mkey
P388 (Murine) NFnqbWlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M1qyRp42KM7:TR?= MoC5SG1UVw>? Ml\WTWM2OD12LkK3JO69VQ>? M1;aVlE6QTl4Mkey
A2780/S NIC3ZXJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MYn+OUDPxE1? MYXEUXNQ MUfJR|UxRTBwMUKyJO69VQ>? M3L1XFE6QTl4Mkey
RDES MW\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NUPUeYdHhjVizszN Mn;VSG1UVw>? MmXsTWM2OD1yLkCxNkDPxE1? MoHRNVk6QTZ{N{K=
B6-T315I (Murine B-ALL) M2jiR2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NUnn[mp4hjVizszN NWHNT3JRTE2VTx?= M4DIfGlEPTB;Mj64N{DPxE1? MnTvNVk6QTZ{N{K=
TOV 112D NUHFW441T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NUPxTVlVhjVizszN NYDaNodVTE2VTx?= MV\JR|UxRTJwMUS2JO69VQ>? NImxNngyQTl7NkK3Ni=>
TC32 M3nWSWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NUna[XNQhjVizszN M1npe2ROW09? NIDi[YVKSzVyPUCuNFA5KM7:TR?= M1[0ZlE6QTl4Mkey
HL60 (acute myelocytic) M2XZVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MlPrglUh|ryP M4LROGROW09? MmTETWM2OD1yLkGyJO69VQ>? NWPwZZp1OTl7OU[yO|I>
TOV 21G Mn\kS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NX\D[WpnhjVizszN M2nDU2ROW09? NWDQcXc6UUN3ME20MlI4QSEQvF2= Ml\4NVk6QTZ{N{K=
TC71 NIT4U3BIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M37zT542KM7:TR?= M1:xW2ROW09? MYrJR|UxRTBwMEG0JO69VQ>? NV3rXFhpOTl7OU[yO|I>
HPN-ALL (T-cell) MlnxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NYfuWHU1hjVizszN MmHVSG1UVw>? MXTJR|UxRTBwNUKg{txO M4q4SFE6QTl4Mkey
A2780R NFTqTpRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3PpcZ42KM7:TR?= Mm\GSG1UVw>? MUnJR|UxRTFwNU[0JO69VQ>? M3joOVE6QTl4Mkey
Rh1 MWnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MnfNglUh|ryP NXnpdW1rTE2VTx?= NX\0VnhLUUN3ME2wMlAzPyEQvF2= MWGxPVk6PjJ5Mh?=
Kasumi-1 (acute myeloid) NIfWU3hIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NUPRWGZJhjVizszN Ml7iSG1UVw>? Mm\OTWM2OD1yLkG2JO69VQ>? NWWxW3lMOTl7OU[yO|I>
sk-ov-3 M4LWe2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MoX1glUh|ryP M1XtV2ROW09? NWfMb2MzUUN3ME21MlEh|ryP NH20d2gyQTl7NkK3Ni=>
ME NFj3SGZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NIDvXYt,PSEQvF2= MnjtSG1UVw>? MWnJR|UxRTBwMEG1JO69VQ>? MnHDNVk6QTZ{N{K=
L1210 (Murine lymphocytic) MYjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M4W3[J42KM7:TR?= M1PrZWROW09? M2nFS2lEPTB;Mj6zPUDPxE1? NIrSd44yQTl7NkK3Ni=>
sw-626 MUPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYSwTVhOhjVizszN MWnEUXNQ NHPMZ5BKSzVyPUKuN|A3KM7:TR?= NELNOncyQTl7NkK3Ni=>
CTR MnraS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MX3+OUDPxE1? MXHEUXNQ MXXJR|UxRTBwMkWzJO69VQ>? NFrLeG4yQTl7NkK3Ni=>
ML2 (Myelomonocytic) Ml;XS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MnHNglUh|ryP M3Hm[WROW09? M4\3WGlEPTB;MD6wPUDPxE1? MVKxPVk6PjJ5Mh?=
ovcar-3 NGTJ[ItIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NEDyfoh,PSEQvF2= MU\EUXNQ M2ThS2lEPTB;NTFOwG0> M16wU|E6QTl4Mkey
Rh36 MWjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MYH+OUDPxE1? NYHDWoRHTE2VTx?= MlzLTWM2OD1zLkSzNkDPxE1? MUOxPVk6PjJ5Mh?=
MOLM-13 (acute myeloid) MWLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MmPvglUh|ryP MknKSG1UVw>? NEDBUIRKSzVyPUCuOFIh|ryP M37EZVE6QTl4Mkey
ovcar-4 MUfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MnnwglUh|ryP MYXEUXNQ NWe4R4xPUUN3ME2xJO69VQ>? NF;JS24yQTl7NkK3Ni=>
Rh41 NFPsXVFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M4XMXZ42KM7:TR?= MUfEUXNQ MoLRTWM2OD1yLkCwOUDPxE1? MmjxNVk6QTZ{N{K=
Mutz 2 (acute myeloid) MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M17lPZ42KM7:TR?= Mle1SG1UVw>? MVrJR|UxRTFwMUWg{txO MYOxPVk6PjJ5Mh?=
ovcar-5 M2HQSmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYD+OUDPxE1? NX3WfIxTTE2VTx?= MmXQTWM2OD1yLkC1JO69VQ>? MmroNVk6QTZ{N{K=
RD1 MXLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M3HYfp42KM7:TR?= MnXkSG1UVw>? MYLJR|UxRTBwME[4JO69VQ>? M3TKTlE6QTl4Mkey
OCI-AML 2 (acute myeloid) NEjtW4VIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHvWRVF,PSEQvF2= MlTVSG1UVw>? NEmyUmZKSzVyPUOuN|Mh|ryP MYixPVk6PjJ5Mh?=
786-O MX;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NGL4PY5,PSEQvF2= M3Kx[2ROW09? MUPJR|UxRTFwNkS3JO69VQ>? MoHUNVk6QTZ{N{K=
A673 M4TNcmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MmH1glUh|ryP NH3zSZdFVVOR M2XlN2lEPTB;MD60NFgh|ryP MWixPVk6PjJ5Mh?=
TALL-1 (T-cell) MXzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MmH5glUh|ryP NETMeHVFVVOR NHLtbo5KSzVyPUGuNlgh|ryP MmjuNVk6QTZ{N{K=
151-B NEjycXdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MYD+OUDPxE1? MnS2SG1UVw>? NUjRdng6UUN3ME2yMlY4KM7:TR?= MnvrNVk6QTZ{N{K=
PFSK-1 NX\PPZA1T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MXX+OUDPxE1? NWHt[4NCTE2VTx?= NVfYUJlLUUN3ME2wMlE{OiEQvF2= MU[xPVk6PjJ5Mh?=
THP-1 MoC0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmXvglUh|ryP NGHxO|NFVVOR NG\zU2VKSzVyPU[uOVgh|ryP M{Tx[FE6QTl4Mkey
HEK293 M1:xbWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1Xxdp42KM7:TR?= NHfib3hFVVOR MUjJR|UxRTBwOUG1JO69VQ>? NIHiZ2UyQTl7NkK3Ni=>
DAOY MkLUS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmPmglUh|ryP NHzUPZRFVVOR NIfjbGVKSzVyPUGuPVc6KM7:TR?= NWrXO2xFOTl7OU[yO|I>
SET2 M{X5VGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NGW2OGp,PSEQvF2= MUnEUXNQ MYDJR|UxRTBwMkm4JO69VQ>? Mli3NVk6QTZ{N{K=
HTB-46 NXL5fFFsT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1LVWp42KM7:TR?= NFfTNVNFVVOR M2roUGlEPTB;NT6yOUDPxE1? M37OOlE6QTl4Mkey
SK-NAS MlrLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MXP+OUDPxE1? NXvvZ4dUTE2VTx?= MUDJR|UxRTBwNEm3JO69VQ>? MnHpNVk6QTZ{N{K=
CTLL2 NXX4PXlwT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NVTDOFl2hjVizszN MYPEUXNQ MXHJR|UxRjFwMECg{txO NHfXUG0yQTl7NkK3Ni=>
HTB-47 M33PbGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MWD+OUDPxE1? Mm\tSG1UVw>? NF7ZSZhKSzVyPUKuNFU3KM7:TR?= M4rBbVE6QTl4Mkey
LAN-1 M2P3SWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MVf+OUDPxE1? NVXsSoRCTE2VTx?= MUTJR|UxRTBwMESg{txO NGXBVVMyQTl7NkK3Ni=>
ST486 MkTxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MnrCglUh|ryP M13ISWROW09? MnjrTWM2OD1zLkG5JO69VQ>? M3LMbVE6QTl4Mkey
HS766T NUnzVndsT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NV\CZY1OhjVizszN MnL0SG1UVw>? NGLLeJdKSzVyPUKuNFAyKM7:TR?= M3\vPFE6QTl4Mkey
IMR-32 MnvQS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Ml\PglUh|ryP M3zHXWROW09? MoHPTWM2OD1yLkK2NUDPxE1? M2O0b|E6QTl4Mkey
Daudi (Burkitt's) Mke3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Mn\6glUh|ryP Mm\NSG1UVw>? M3vHbWlEPTB;Mj62N|ch|ryP M2fLO|E6QTl4Mkey
Aspc-1 Ml3CS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MYT+OUDPxE1? M2PIfGROW09? MWjJR|UxRTBwM{e5JO69VQ>? NW\aS2dWOTl7OU[yO|I>
SK-NSH NG[yfZFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NE\vSGd,PSEQvF2= M{jkbGROW09? NV7yR3V2UUN3ME2wMlE{QSEQvF2= NF;ZWmUyQTl7NkK3Ni=>
MEC-1 (Chronic B cell) MWrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NIi1doF,PSEQvF2= NXrHVGJ3TE2VTx?= NVvCT5liUUN3ME2yMlY{PyEQvF2= Ml;HNVk6QTZ{N{K=
Capan-2 NHHsOlJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MXf+OUDPxE1? M1nXdWROW09? NYG2eFk4UUN3ME2xMlc4PCEQvF2= M33JRVE6QTl4Mkey
SHSY5Y NFHObZBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MWH+OUDPxE1? NY\EeIRWTE2VTx?= NVHRfHNoUUN3ME2wMlExPiEQvF2= MU[xPVk6PjJ5Mh?=
U937 (Histioocytic) NVjUSG9wT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4TqcJ42KM7:TR?= NWnRUYROTE2VTx?= MX;JR|UxRjVwMECg{txO NF7xSJIyQTl7NkK3Ni=>
Bxpc-1 NYXBe2dwT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NXvYWVFMhjVizszN MUjEUXNQ MnTYTWM2OD1zLkmyOEDPxE1? NHjmemcyQTl7NkK3Ni=>
Bxpc-3 M1LJd2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NHjHb2N,PSEQvF2= M4PwWmROW09? M1izUmlEPTB-NT6wNEDPxE1? M4jQRVE6QTl4Mkey
HTB-92 NIm1XoFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MoLCglUh|ryP NFXhWFZFVVOR M4r5bWlEPTB;MT6wNkDPxE1? NGfHfGoyQTl7NkK3Ni=>
OCI-LY10 (B-cell) NXnKWW1{T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NU\LPFkxhjVizszN NYXrSnJnTE2VTx?= M2\H[GlEPTB;MD60OUDPxE1? MV2xPVk6PjJ5Mh?=
PANC-1 Mmn2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MnW1glUh|ryP MX7EUXNQ MnLWTWM2OD53LkCwJO69VQ>? NHnTeHEyQTl7NkK3Ni=>
To184.T Mln2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXLKdot2hjVizszN NFfYUXJFVVOR MVrJR|UxRTBwNE[5JO69VQ>? NXnEfXRTOTl7OU[yO|I>
OCI-LY19 (B-cell) M37VNmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MX3+OUDPxE1? NVzSVYh7TE2VTx?= MoK1TWM2OD1yLkSg{txO NHvXeGsyQTl7NkK3Ni=>
PANC-1 BM NEe3cHlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3jpVp42KM7:TR?= NUHaR|lkTE2VTx?= M4TJRmlEPTB-NT6wNEDPxE1? NX;DOnRIOTl7OU[yO|I>
SA-4 MV;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MVv+OUDPxE1? MlHHSG1UVw>? NVTTcIM4UUN3ME2xMlMxOSEQvF2= NYTTSI1[OTl7OU[yO|I>
RPMI 8226 NYDteWhtT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1fBNJ42KM7:TR?= MUHEUXNQ NW\je5ZtUUN3ME2xMlI6OyEQvF2= MoPQNVk6QTZ{N{K=
HPAF-II MnXuS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M4\zeZ42KM7:TR?= Mo\DSG1UVw>? NXfEZWdKUUN3ME2wMlY1PCEQvF2= MnLINVk6QTZ{N{K=
SHP-77 MkLrS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MXX+OUDPxE1? NUDMZ|VmTE2VTx?= NHK4XI5KSzVyPUGuPFg5KM7:TR?= NUKxXmNsOTl7OU[yO|I>
U266 B1 Mn\xS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1fMU542KM7:TR?= NGnUOVJFVVOR NFXHfWlKSzVyPUGuOlY6KM7:TR?= MYexPVk6PjJ5Mh?=
Hs700t MkK1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NUfoN2FnhjVizszN MnLRSG1UVw>? NX[wRY1{UUN3ME2wMlI{OSEQvF2= NHHIXowyQTl7NkK3Ni=>
NCI-446 MXPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NF;FVGl,PSEQvF2= MYnEUXNQ MWnJR|UxRTFwMUW0JO69VQ>? NGPlWGwyQTl7NkK3Ni=>
H929 M1zuemdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Ml:xglUh|ryP MkXESG1UVw>? NVjoUHlFUUN3ME2wMlAyPCEQvF2= MWmxPVk6PjJ5Mh?=
PL45 NETNWHpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MVj+OUDPxE1? NIHWNlVFVVOR M4DNTGlEPTB;Mj6yOVUh|ryP MnfpNVk6QTZ{N{K=
NCI-H383 NWm4XGl{T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MlfaglUh|ryP NGHuXXhFVVOR NIPFOJZKSzVyPkWuNFAh|ryP MXyxPVk6PjJ5Mh?=
JJN3 MkT2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1i3T542KM7:TR?= M13mZmROW09? M{Hh[mlEPTB;Mj60N|Mh|ryP MX6xPVk6PjJ5Mh?=
SU.86.86 MnT0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M4Xqbp42KM7:TR?= NHHDWWdFVVOR MX7JR|UxRTJwNkeyJO69VQ>? MnX4NVk6QTZ{N{K=
H1299 NFjPTINIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MYX+OUDPxE1? M4rnRmROW09? MWPJR|UxRjVwMECg{txO NETROVMyQTl7NkK3Ni=>
MDA-MB-468 MmTZS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Moq1glUh|ryP MoewSG1UVw>? NF3RTFFKSzVyPUCuOVA1KM7:TR?= MoGzNVk6QTZ{N{K=
SW1990 MojCS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFPSdnF,PSEQvF2= NFTOXYJFVVOR NYDEcphDUUN3ME2wMlgzPiEQvF2= M1jWb|E6QTl4Mkey
Calu-6 MYPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mo\KglUh|ryP M17MVGROW09? M3yzbGlEPTB-NT6wNEDPxE1? MVmxPVk6PjJ5Mh?=
MDA-MB-231 NFjTTnFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MkK5glUh|ryP NEHl[FlFVVOR Mn25TWM2OD1zLk[0PEDPxE1? M1jMSVE6QTl4Mkey
SW-684 NXy2[pQxT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NEHkenl,PSEQvF2= Mk\vSG1UVw>? NYm3UZhpUUN3ME61MlAxKM7:TR?= MYmxPVk6PjJ5Mh?=
H209 MUTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2PMcJ42KM7:TR?= NHfQS5NFVVOR MWrJR|UxRTFwMUmzJO69VQ>? MU[xPVk6PjJ5Mh?=
MDA-MB-231T NEnET5NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3;rNp42KM7:TR?= NVOxeJB3TE2VTx?= MV\JR|UxRjVwMECg{txO M4rteVE6QTl4Mkey
HT1080/S M1vCVWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NUDtcmM5hjVizszN MoPlSG1UVw>? Mm\QTWM2OD1yLkWzNUDPxE1? Mo\zNVk6QTZ{N{K=
H526 0.044 M2PRbGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NU\QOGh{hjVizszN Mof4SG1UVw>? MoXhTWM2OD1yLkC0OEDPxE1? M3fEVFE6QTl4Mkey
DU4475 2.431 MmfkS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MWj+OUDPxE1? NUnCOGlNTE2VTx?= Ml7MTWM2OD1{LkSzNUDPxE1? MV2xPVk6PjJ5Mh?=
HCT116 NEDxW2ZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MoOyglUh|ryP MmC2SG1UVw>? MljYTWM2OD1yLki1NkDPxE1? NGfLZYIyQTl7NkK3Ni=>
M109 MoPzS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M2W5eJ42KM7:TR?= MlrvSG1UVw>? M4\0UmlEPTB;MT6wOVUh|ryP MmDTNVk6QTZ{N{K=
BT549 MWrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MWf+OUDPxE1? NIezToxFVVOR NIrjWXhKSzVyPUGuOlQ2KM7:TR?= NYS1WIZLOTl7OU[yO|I>
HCT116/VM46 NIfmdHpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2jiTp42KM7:TR?= NVnofJZkTE2VTx?= MYLJR|UxRTFwN{CyJO69VQ>? NFrTRVkyQTl7NkK3Ni=>
H460 MWTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MWP+OUDPxE1? Ml;nSG1UVw>? M1jHT2lEPTB;MD63PVUh|ryP M1nx[FE6QTl4Mkey
MCF-7 Mn\OS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmTTglUh|ryP M2PTSGROW09? NYj0Z4Y{UUN3ME2wMlAyPiEQvF2= NU\sb282OTl7OU[yO|I>
GEO M3n6NWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NWnMcoxphjVizszN M3yxUmROW09? M3TCTWlEPTB;MD6zOVYh|ryP Ml;5NVk6QTZ{N{K=
H441 0.646 M3jvUGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MV7+OUDPxE1? NVmzSVltTE2VTx?= NFf4fnlKSzVyPUCuOlQ3KM7:TR?= MkLoNVk6QTZ{N{K=
MCF-7-807R MVjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYW4ZYR7hjVizszN NWDaSFlPTE2VTx?= M1W5dWlEPTB;MD60PUDPxE1? MYCxPVk6PjJ5Mh?=
Colo205 NIi3SY1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MUj+OUDPxE1? MVzEUXNQ M4X3PGlEPTB;MD6xNFQh|ryP MYOxPVk6PjJ5Mh?=
H292 NFq2VZVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MkfGglUh|ryP MVrEUXNQ MWrJR|UxRTBwN{i4JO69VQ>? MWSxPVk6PjJ5Mh?=
BT474 (S) NH2wRm1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NVLQWHVphjVizszN M4nWS2ROW09? MXXJR|UxRTJwNECzJO69VQ>? NYfPSJM5OTl7OU[yO|I>
HT-29 MkmyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NF;IUHJ,PSEQvF2= NVjzdHdHTE2VTx?= NFXJSnBKSzVyPUKuNVA{KM7:TR?= Mnq2NVk6QTZ{N{K=
A549 M1zjTmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Ml;BglUh|ryP NWXzcGx{TE2VTx?= NVu3OYg2UUN3ME2wMlY4PSEQvF2= MU[xPVk6PjJ5Mh?=
BT474-M1 MoPES5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmTNglUh|ryP M1nTOGROW09? Mmi5TWM2OD1{LkO2OUDPxE1? MYOxPVk6PjJ5Mh?=
SW480 NVrn[XRjT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NUS1V2p1hjVizszN M1jOTGROW09? MofRTWM2OD53LkCwJO69VQ>? NF62XXgyQTl7NkK3Ni=>
L2987 M3nq[Wdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXf+OUDPxE1? NEXCV3VFVVOR M{LD[WlEPTB;MD60OFIh|ryP NXLEbopJOTl7OU[yO|I>
AU565 MWfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MoXlglUh|ryP NEL4U2RFVVOR Mn\FTWM2OD12Lkm3JO69VQ>? M4TTbFE6QTl4Mkey
SW403 NF:zWVZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3jGcp42KM7:TR?= MXHEUXNQ NXO5O3dnUUN3ME2wMlIzKM7:TR?= M1nle|E6QTl4Mkey
H1437 NULDe2RCT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MWD+OUDPxE1? M{TNcmROW09? NES1ZpRKSzVyPUCuOVI{KM7:TR?= NFrBbZAyQTl7NkK3Ni=>
BT-20 MorwS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MVr+OUDPxE1? MYPEUXNQ M{jscGlEPTB;Mz61OlIh|ryP MoDUNVk6QTZ{N{K=
Colo320HSR Mn35S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MknUglUh|ryP MkPJSG1UVw>? NY[4UmpnUUN3ME2wMlAyOSEQvF2= MlzFNVk6QTZ{N{K=
H2087 NF35TGZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NEC0b|V,PSEQvF2= NWnRVGlqTE2VTx?= NHfod5lKSzVyPkGuNFAh|ryP MoLONVk6QTZ{N{K=
HCC1419 M1G1cWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXvmfIE{hjVizszN MoC4SG1UVw>? MUHJR|UxRTJwNUG3JO69VQ>? Mk[3NVk6QTZ{N{K=
WiDr MlnpS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MWf+OUDPxE1? Mlq3SG1UVw>? MnfvTWM2OD1yLkC3OkDPxE1? MYOxPVk6PjJ5Mh?=
H661 0.573 MkjBS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MXv+OUDPxE1? NVLSWFFuTE2VTx?= MYTJR|UxRTBwNUezJO69VQ>? NWrxdJlDOTl7OU[yO|I>
HCC-38 NG\LPIFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NV3mS21PhjVizszN M3fFXmROW09? NUPq[noxUUN3ME61MlAxKM7:TR?= MWKxPVk6PjJ5Mh?=
LS174T Mo\mS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHXwTZF,PSEQvF2= MknhSG1UVw>? NUnXbG1YUUN3ME2wMlU{PSEQvF2= M37Ob|E6QTl4Mkey
H211 MkTSS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MWL+OUDPxE1? MkHRSG1UVw>? MX3JR|UxRTBwN{OzJO69VQ>? MkXyNVk6QTZ{N{K=
HCC70 M2P3RWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1X5PZ42KM7:TR?= Ml\FSG1UVw>? MmHTTWM2OD1zLkW1JO69VQ>? NYGweXd4OTl7OU[yO|I>
SW116 MorWS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFX3enN,PSEQvF2= MUfEUXNQ Mn;XTWM2OD1yLkC2O{DPxE1? NIfXcGcyQTl7NkK3Ni=>
H513 NWfQXmVnT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NF7EcWp,PSEQvF2= NV\nPY1DTE2VTx?= M4L6SWlEPTB;ND60OFgh|ryP NH7JU5YyQTl7NkK3Ni=>
MDA-MB-157 MnvOS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NVTDTXJ7hjVizszN M370emROW09? MoCwTWM2OD1yLkCzOkDPxE1? NIfDd4kyQTl7NkK3Ni=>
H2052 Mo\kS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1;aZZ42KM7:TR?= NInYWplFVVOR M3L0[mlEPTB;MT6wOUDPxE1? M1LXflE6QTl4Mkey
MDA-MB-415 NXLiWHJIT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MnzIglUh|ryP NYm0fG5MTE2VTx?= NXm1eXRqUUN3ME61MlAxKM7:TR?= NFTEZ3QyQTl7NkK3Ni=>
DLD-1 MYLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M4\Hfp42KM7:TR?= NG\3WmNFVVOR M4TUNGlEPTB;MD65NFkh|ryP MV:xPVk6PjJ5Mh?=
H2595 NGnIdpRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MljJglUh|ryP M3\4TGROW09? NYfyb3pYUUN3ME20MlQ4PSEQvF2= MkLiNVk6QTZ{N{K=
MDA-MB-435S NH;SZ3NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MlqxglUh|ryP MnKxSG1UVw>? MYTJR|UxRTFwOE[5JO69VQ>? MYexPVk6PjJ5Mh?=
HCT15 M1vTd2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYL+OUDPxE1? NYrrUnZtTE2VTx?= MXXJR|UxRjFwMECg{txO NFnwWHoyQTl7NkK3Ni=>
SK-Hep1 NG\zV|hIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= Mm[wglUh|ryP MUXEUXNQ NUXpZlFXUUN3ME2wMlE1PiEQvF2= NYHaPWo3OTl7OU[yO|I>
MDA-MB-436 NV;EcFkzT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MV\+OUDPxE1? NVnvNYN6TE2VTx?= NHX1PIxKSzVyPUWuOVAzKM7:TR?= MmjSNVk6QTZ{N{K=
KM12C MnzYS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1;SR542KM7:TR?= MmPOSG1UVw>? M1\lTWlEPTB;MD6wOVQh|ryP MWSxPVk6PjJ5Mh?=
HEPG2 M4DaTGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M{LSeJ42KM7:TR?= Mn7QSG1UVw>? NHrKOWFKSzVyPUCuNFI2KM7:TR?= MWixPVk6PjJ5Mh?=
MDA-MB-453 NGfmdmxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2[x[J42KM7:TR?= M2fUVGROW09? M4X2c2lEPTB;MT64Olkh|ryP NFPaSYYyQTl7NkK3Ni=>
KM12SM M3rCWGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXH+OUDPxE1? NHjX[XlFVVOR NGDi[IZKSzVyPUCuNFU6KM7:TR?= NGLVOFcyQTl7NkK3Ni=>
1483 Ml;5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Mmf5glUh|ryP M3PPSmROW09? MXfJR|UxRTJwMUmg{txO MYexPVk6PjJ5Mh?=
Hs578t NYm1c5Y3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MmDTglUh|ryP NYTLWpNnTE2VTx?= M3nPXWlEPTB;MT6yPFch|ryP MVmxPVk6PjJ5Mh?=
LS180 MV3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MUj+OUDPxE1? MoL0SG1UVw>? NIn3[phKSzVyPUCuOlk3KM7:TR?= M4HKZ|E6QTl4Mkey
FaDu M{Puemdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NFvlO3d,PSEQvF2= NXz6UIFYTE2VTx?= NELWfJVKSzVyPUGuNlch|ryP MkTTNVk6QTZ{N{K=
ZR-75-1 Mn7aS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MVv+OUDPxE1? MV;EUXNQ MnrSTWM2OD1{LkC4OEDPxE1? M2TGZ|E6QTl4Mkey
LS513 NW\Vc3JvT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M3n5VJ42KM7:TR?= NVPHNFBqTE2VTx?= NXrWfWZnUUN3ME2wMlE{PSEQvF2= NIPBc4UyQTl7NkK3Ni=>
Detroit.562 NYrUSYhOT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1\Be542KM7:TR?= MYHEUXNQ MlnGTWM2OD1zLkG0JO69VQ>? MYexPVk6PjJ5Mh?=
ZR-75-30 Mk[5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M{L5[Z42KM7:TR?= MkXNSG1UVw>? MUnJR|UxRjVwMECg{txO NYPtbZRSOTl7OU[yO|I>
RKO-PM NXXjXoI4T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NV[2T49{hjVizszN NYX2[|JzTE2VTx?= NX64WJJ7UUN3ME2wMlI{OiEQvF2= MmDENVk6QTZ{N{K=
Cal.27 Mk\HS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NEDWc2V,PSEQvF2= M1XQO2ROW09? Mkn5TWM2OD1{IN88US=> MmrkNVk6QTZ{N{K=
KPL4 M3PJPWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NYHQWWRIhjVizszN NYHzZ3FJTE2VTx?= MnHITWM2OD1zLkK1NkDPxE1? MUixPVk6PjJ5Mh?=
PKO-RM13 MX\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NWT5cGdmhjVizszN MkjWSG1UVw>? MXzJR|UxRTBwNEK1JO69VQ>? MXuxPVk6PjJ5Mh?=
HS.53.T MXTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFntZWF,PSEQvF2= NVzM[pMyTE2VTx?= NYnYOGoxUUN3ME2wMlc6KM7:TR?= M1P0eFE6QTl4Mkey
EMT6 NWK2W2VWT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NYDQXZVmhjVizszN NVntVJAyTE2VTx?= MW\JR|UxRTBwOEC2JO69VQ>? NXXHO414OTl7OU[yO|I>
SNU-C1 NHvLO|NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M4HIWp42KM7:TR?= M3ywZWROW09? M1LLOWlEPTB;MD6wNFch|ryP MlL6NVk6QTZ{N{K=
SQCCY1 NV\BflJRT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MmnzglUh|ryP MoXvSG1UVw>? MX;JR|UxRTBwN{mg{txO MVyxPVk6PjJ5Mh?=
SW480 M4foS2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NFn2SJV,PSEQvF2= M1rQfWROW09? MnX6TWM2OD1yLkCzO{DPxE1? NXnZNmN4OTl7OU[yO|I>
SCC9 NUX1PGNUT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MX3+OUDPxE1? MkPLSG1UVw>? MoPaTWM2OD1yLke1JO69VQ>? NXmzNlExOTl7OU[yO|I>
SK-LMS-1 NFfQRXhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NX3NRoFGhjVizszN M17xR2ROW09? Mn\TTWM2OD1yLk[4O{DPxE1? MWqxPVk6PjJ5Mh?=
SCC25 MlXrS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MUX+OUDPxE1? NYn1b242TE2VTx?= NV7COoE6UUN3ME2wMlY5KM7:TR?= MY[xPVk6PjJ5Mh?=
U87 NEXvfFBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2XH[p42KM7:TR?= NU\wTm1jTE2VTx?= MYnJR|UxRTBwOUWg{txO NIfX[JYyQTl7NkK3Ni=>
SCC15 NUPGVow1T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NXPEV3MyhjVizszN NWSyfGdUTE2VTx?= M{TVV2lEPTB;MD62O{DPxE1? M1nBelE6QTl4Mkey
T98G M3\tTGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NIjjZlh,PSEQvF2= NV:5WGxGTE2VTx?= MlHWTWM2OD1zLkKxPEDPxE1? NFrNVpMyQTl7NkK3Ni=>
SCC4 MX\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NEjhT2l,PSEQvF2= NU\wd3ZYTE2VTx?= M37CVGlEPTB;MD62N{DPxE1? NW\XTWQ1OTl7OU[yO|I>
U118 NHHvclFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MmT1glUh|ryP NInyenNFVVOR NXnYZnhjUUN3ME2xMlYyQCEQvF2= NVK1WG51OTl7OU[yO|I>
TU167 NHLEdINIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NWmxTGNwhjVizszN M3yycmROW09? M171O2lEPTB;ND61NkDPxE1? NHnTcJQyQTl7NkK3Ni=>
NCI-H727 NHTRZWJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MlzMglEx6oDMzszN NGPMbIlFVVOR NV7V[nZ3UUN3ME20Nlghdk1? M2nqbFIxOzh3N{S3
NCI-H720 M4e3UGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MkC0glEx6oDMzszN MonOSG1UVw>? MYHJR|UxRTJwODFOwG0> NF;JPJozODN6NUe0Oy=>
NCI-H835 NV62U4ljT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NVj6XJhohjFy4pEK{txO MWDEUXNQ M{DoZmlEPTB;MTFOwG0> NHy2NY4zODN6NUe0Oy=>
NCI-H727 M2HDXGtqdmG|ZTDhd5NigQ>? MnfHglEx6oDMzszN M4fhOmROW09? MnrIbY5pcWKrdIOgZ49ve3SrdIX0bZZmKEmJRkHSJIF2fG:yaH;zdIhwenmuYYTpc44> Ml;DNlA{QDV5NEe=
RD NHjpV4pIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NH32RZp,OTEkgJtOwG0> NFrmcIFKSzVyPUGuNVIhyrWP MnLONlEzQTh5NEW=
Rh41 M1\Mcmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MorKglEx6oDMzszN M2f3cWlEPTB;MD6wO{DDvU1? NFOzbVMzOTJ7OEe0OS=>
Rh18 MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MV;+NVDjiIsQvF2= M{fq[mlEPTB;ND65OkDDvU1? NYD1fW5IOjF{OUi3OFU>
Rh30 MWPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MYH+NVDjiIsQvF2= M{TXcmlEPTB;MD6xPUDDvU1? NF\BdVczOTJ7OEe0OS=>
BT-12 NE\XbWZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M364[J4yOOLCit88US=> NHjUVZVKSzVyPUCuO|ghyrWP NFHsU3ozOTJ7OEe0OS=>
CHLA-266 M4PoWGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYf+NVDjiIsQvF2= Mn7JTWM2OD1yLki5JOK2VQ>? MkXzNlEzQTh5NEW=
TC-71 MWfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MoW0glEx6oDMzszN NX\0OVRqUUN3ME2wMlEyKML3TR?= MoO3NlEzQTh5NEW=
CHLA-9 M{jJVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2P1TZ4yOOLCit88US=> MofqTWM2OD1yLkGyJOK2VQ>? MXiyNVI6QDd2NR?=
CHLA-10 M1fuW2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYD+NVDjiIsQvF2= Mk\5TWM2OD1yLk[yJOK2VQ>? NYHjbpJuOjF{OUi3OFU>
CHLA-258 MULHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NI\WeXZ,OTEkgJtOwG0> MnfDTWM2OD1yLkK3JOK2VQ>? NFX5dFYzOTJ7OEe0OS=>
GBM2 M4HWfGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MV;+NVDjiIsQvF2= M3XJfmlEPTB;MT60O{DDvU1? MYqyNVI6QDd2NR?=
NB-1643 NFfCbXdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M4TDeJ4yOOLCit88US=> MUnJR|UxRTBwMUKgxtVO M4LEUlIyOjl6N{S1
NB-EBc1 NUPNVnc1T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MVz+NVDjiIsQvF2= M3[5VGlEPTB;MD6zOUDDvU1? NVXRTZRGOjF{OUi3OFU>
CHLA-90 M{PVUGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NFfhTG9,OTEkgJtOwG0> M2fkN2lEPTB;MD63O{DDvU1? NVvLeVg{OjF{OUi3OFU>
CHLA-136 NXrPUIVNT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NUO2eWdVhjFy4pEK{txO MV7JR|UxRTBwNUKgxtVO NX:2OXF[OjF{OUi3OFU>
NALM-6 MonsS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MnTJglEx6oDMzszN MYjJR|UxRTBwNEmgxtVO NEDuUJEzOTJ7OEe0OS=>
COG-LL-317 NFi0S|NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NVfQUmQxhjFy4pEK{txO M320N2lEPTB;MT6zPEDDvU1? MUiyNVI6QDd2NR?=
RS4;11 NGrIfVNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NFrPRmt,OTEkgJtOwG0> NXXIXVlIUUN3ME2wMlM5KML3TR?= MkHNNlEzQTh5NEW=
MOLT-4 MVjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NUi2dI5FhjFy4pEK{txO NXq1TXRzUUN3ME2wMlU{KML3TR?= MmT1NlEzQTh5NEW=
CCRF-CEM MVXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M{X3dZ4yOOLCit88US=> MXvJR|UxRTFwMUOgxtVO NFnVdVMzOTJ7OEe0OS=>
Kasumi-1 NETmc|RIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2PjdJ4yOOLCit88US=> MkLSTWM2OD1zLkKgxtVO MmPRNlEzQTh5NEW=
Karpas-299 M{\GcWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYD+NVDjiIsQvF2= M{i2SWlEPTB;MT62OEDDvU1? M3nobFIyOjl6N{S1
Ramos-RA1 MmHWS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MY\+NVDjiIsQvF2= M4TteGlEPTB;MT6zNUDDvU1? NUD4fXhLOjF{OUi3OFU>
Rh30  M4TWU2Z2dmO2aX;uJIF{e2G7 M4mzeYlv\HWlZYOgZY4hcW6lcnXhd4Uhd2ZiU1\LJJBpd3OyaH;yfYxifGmxbh?= MmrsNlU6OjV|N{i=
Rh41 MXLGeY5kfGmxbjDhd5NigQ>? MojXbY5lfWOnczDhckBqdmO{ZXHz[UBw\iCVRlugdIhwe3Cqb4L5cIF1cW:w NIHBT4YzPTl{NUO3PC=>
RD M2\1UWZ2dmO2aX;uJIF{e2G7 NH7mfW9qdmS3Y3XzJIFvKGmwY4LlZZNmKG:oIGPGT{BxcG:|cHjvdplt[XSrb36= M3HLVVI2QTJ3M{e4
A549 M{O3OWtqdmG|ZTDhd5NigQ>? M2m1XVAvPeLCit88US=> NHrYXGJFVVOR M1mxb4lvcGmkaYTzJGlITi2LUj;JVkBi[3SrdnH0bY9v NYfOUVZxOjZ7Mki1O|g>
NCI-H358 MmS4T4lv[XOnIHHzd4F6 MVewMlXjiIsQvF2= NUXmeXZ[TE2VTx?= NYWyXmpCcW6qaXLpeJMhUUeILVnSM2lTKGGldHn2ZZRqd25? NYXZdpN[OjZ7Mki1O|g>
A549 MlrXSpVv[3Srb36gZZN{[Xl? NYPZcHpuOC534pEK{txO NFT6fYVFVVOR M2XLWINifXOnczDhJINwdmO3coLlcpQh\GWlcnXhd4UhcW5icHjvd5Bpd3K7bHH0[YQhSUuWIHHu[EBGWkt? NWDWOFQzOjZ7Mki1O|g>
NCI-H358 MWXGeY5kfGmxbjDhd5NigQ>? NGrQNoExNjYkgJtOwG0> NVP0OYl5TE2VTx?= M3fhVINifXOnczDhJINwdmO3coLlcpQh\GWlcnXhd4UhcW5icHjvd5Bpd3K7bHH0[YQhSUuWIHHu[EBGWkt? NIHvPHAzPjl{OEW3PC=>
A549 Mlz3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M3zQNp4yOOLCit88US=> MVzEUXNQ NWHqfGJXUUN3ME2wMlc3KM7:TR?= M2W0RVI3QTJ6NUe4
NCI-H358 NWHUfY9xT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MXT+NVDjiIsQvF2= M1rjcGROW09? NYPkdYR3UUN3ME2xMlA6KM7:TR?= MX6yOlkzQDV5OB?=
A549 NGS2NGtCeG:ydH;zbZMh[XO|YYm= NXraRpZvOC534pEK{txO M1zLdGROW09? M1TzeIlv\HWlZYOgRZBweHSxc3nz MmTCNlY6Ojh3N{i=
NCI-H358 MnrsRZBweHSxc3nzJIF{e2G7 NIe2NWIxNjYkgJtOwG0> M3SzT2ROW09? M1r2T4lv\HWlZYOgRZBweHSxc3nz NF3TWVMzPjl{OEW3PC=>
A549 NY\sblc5TnWwY4Tpc44h[XO|YYm= MkPzNE426oDMzszN M4fZVmROW09? NXO5d5lnemWmdXPld{B4d3WwZDDjcI9{fXKn MoXhNlY6Ojh3N{i=
NCI-H358 NIXkfWNHfW6ldHnvckBie3OjeR?= NFzM[VMxNjYkgJtOwG0> MWjEUXNQ NFPtZmVz\WS3Y3XzJJdwfW6mIHPsc5N2emV? MoL1NlY6Ojh3N{i=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-IGFIRRβ/InsRβ / IGFIRβ / p-AKT / AKT / p-ERK / ERK ; 

PubMed: 26136493     


(C) T4105 cells were treated with OSI-906 or BMS-754807 at indicated concentrations for 24 hours, lysed, and subjected to immunoblotting.

26136493
Growth inhibition assay
Cell viability; 

PubMed: 30754629     


Response of SK-CO-1 to various drugs and drug combinations.

30754629
体内研究 BMS-754807(12.5mg/kg,口服)作用于携带 IGF-1R-Sal肿瘤的裸鼠,抑制肿瘤和血清中IGF-1R磷酸化。BMS-754807作用于一组选定的上皮(IGF-1R-Sal, GEO, 和Colo205),造血(JJN3)和间质(RD1和Rh41)移植瘤模型,抑制肿瘤生长,肿瘤生长抑制率从53%至115%不等。[1] BMS-754807 (6.25 mg/kg) 作用于转基因的IGF-Sal肿瘤小鼠模型,完全抑制肿瘤生长,且抑制pIGF-1R 和 pAKT。BMS-754807与小鼠血浆和人类血浆的蛋白结合率分别为98.5% 和95.9%。BMS-754807 (25 mg/kg)作用于携带KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), 和 OS-1移植瘤的小鼠模型,显著抑制肿瘤。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

激酶抑制实验:

在体外激酶实验中使用重组人类 IGF-1受体酶测定BMS-754807,在生化实验中使用合成肽KKSRGDYMTMQIG 作为磷酸受体底物测定BMS-754807。在Ubottom 384孔板中使用 30 μL实验缓冲液 (100 mM Hepes pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT)来进行酶活测定。通过结合ATP,1.5 μM 荧光标记肽底物, 酶和BMS-754807而开始反应,反应持续60分钟。加入EDTA终止反应。通过电泳分离荧光底物和磷酸化产物,然后在Caliper LabChip 3000上分析反应混合物。通过对剂量反应曲线进行非线性回归分析而获得IC50值。
细胞实验:[1]
- 合并
  • Cell lines: IGF-1R-Sal, RH41 和 Geo 细胞系
  • Concentrations: 365 nM
  • Incubation Time: 72 小时
  • Method: 细胞按最佳密度培养在RPMI + GLUTAMAX培养基中,培养基中含有有10% 热灭活的胎牛血清(FBS),10mMHepes,青霉素和链霉素。BMS-754807处理细胞72小时后,通过测定3H-胸甘渗透到DNA中的程度而测评细胞增殖。结果表示为IC50。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 携带IGF-1R-Sal, GEO, Colo205, JJN3, RD1 或 Rh41 肿瘤的裸鼠
  • Dosages: 150 mg/kg
  • Administration: 口服
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 92 mg/mL (199.35 mM)
Ethanol 92 mg/mL (199.35 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 461.49
化学式

C23H24FN9O

CAS号 1001350-96-4
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

相关IGF-1R产品

Tags: 购买BMS-754807 | BMS-754807供应商 | 采购BMS-754807 | BMS-754807价格 | BMS-754807生产 | 订购BMS-754807 | BMS-754807代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID